Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Clin Cancer Res. 2014 Sep 1;20(17):4499–4510. doi: 10.1158/1078-0432.CCR-14-0348

Table 1.

Distribution of the KRAS 3′-UTR LCS6 genotypes according to mutation, clinical and demographic data in the mCRC patients’ cohort

TG TT or GG
N % N % p-value
Age (median, min - max) 61 22 - 89 61 37 - 80 0.654
SEX
 Male 229 57.4 59 54.6 0.662
 Female 170 42.6 49 45.4
KRAS status
 Mutant 138 36.3 36 34.6 0.818
 Wild type 242 63.7 68 65.4
BRAF status
 Mutant 17 4.3 11 10.2 0.030
 WT 379 95.7 97 89.8
TREATMENT
 Monotherapy 128 32.1 32 29.6 0.726
 Combination 271 67.9 76 70.4